We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
- Authors
Takada, Kazuki; Yoneshima, Yasuto; Tanaka, Kentaro; Okamoto, Isamu; Shimokawa, Mototsugu; Wakasu, Sho; Takamori, Shinkichi; Toyokawa, Gouji; Oba, Taro; Osoegawa, Atsushi; Tagawa, Tetsuzo; Oda, Yoshinao; Nakanishi, Yoichi; Mori, Masaki
- Abstract
Purpose: The aim of this study was to elucidate the clinical impact of skeletal muscle area (SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed cell death-1 (PD-1) inhibitors. Methods: Univariate and multivariate analyses were performed on data of 103 patients with advanced or recurrent NSCLC treated with anti-PD-1 inhibitors. The SMA was measured at the level of the third lumbar vertebral (L3) on computed tomography images using OsiriX software (32-bit, version 5.8; OsiriX, Geneva, Switzerland). The L3 muscle index (cm2/m2) was defined as the SMA (cm2) at the L3 level divided by the height (m) squared. Results: L3 muscle index Low was an independent predictor of both progression-free (P = 0.0399) and overall survival (P = 0.0155). Moreover, the disease control rate was significantly lower in the L3 muscle index Low group (49.0% [25/51]) than in the L3 muscle index High group (73.1% [38/52]; P = 0.0117). However, there was no significant difference between the response rates of the L3 muscle index Low group (21.6% [11/51]) and L3 muscle index High group (32.7% [17/52]; P = 0.2031). Conclusions: L3 muscle index Low is an independent predictor of worse outcomes in NSCLC patients treated with anti-PD-1 inhibitors.
- Subjects
GENEVA (Switzerland); NON-small-cell lung carcinoma; SKELETAL muscle
- Publication
Journal of Cancer Research & Clinical Oncology, 2020, Vol 146, Issue 5, p1217
- ISSN
0171-5216
- Publication type
Article
- DOI
10.1007/s00432-020-03146-5